Attenuation of Neuronal Tissue Damage in Ischemic Stroke by Tat-NR2Bct-CTM and Tat-NR2B9c
DOI:
https://doi.org/10.20961/magnaneurologica.v1i2.647Keywords:
DAPK1, PSD-95, stroke, Tat-NR2B9c, Tat-NR2Bct-CTMAbstract
Background: Worldwide, stroke accounts for 15 million cases annually. Despite improved understanding of its pathophysiology, an effective treatment is yet to be available. This review aims to expound ischemic stroke pathophysiology from a bio-molecular perspective, and present two peptides, namely Tat-NR2B9c and Tat-NR2Bct-CTM, which has been proven to attenuate neuronal tissue damage in ischemic stroke.
Methods: Scoping review of several electronic databases: PubMed, Medline, Researchgate, NCBI, SpringerLink, and Google scholar. Search query included: ischemic stroke, NR2B, DAPK1, nNOS, NOX, Tat-NR2Bct-CTM and Tat-NR2B9c.
Results: It is recognizable in a sense, that the pathophysiology pivots on the NR2B-DAPK1 and PSD-95-NR2B interactions. Tat-NR2Bct-CTM and Tat-NR2B9c thwarts NR2B-DAPK1 and PSD-95-NR2B interactions, respectively. These peptides show significant reliability, with the former capable of reducing free DAPK1 by 92,85%, and the latter, the first stroke treatment in two decades to reach Phase 3 clinical trials.
Conclusion: These results strongly support Tat-NR2Bct-CTM and Tat-NR2B9c as effective means to reduce neuronal tissue damage in ischemic stroke.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Benedictus, Kenneth Tan, Vincent Kurniawan Putra Pratama, Jonathan Daniel Sulastyo
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
